Table 2. Meta-analyses reporting neurologic symptoms in patients with COVID-19

First author (date of publication) Study period Number of studies/participants Prevalence of symptoms (95% CI)
Groff (Oct 13, 2021) Dec 2019 to Mar 2021 57/250,351 Memory deficits 18.6% (IQR, 17.3% to 22.9%Cognitive impairment 17.1% (IQR, 14.1% to 30.5%)Headache 8% (IQR, 1.9% to 13.9%)
Lopez-Leon (Aug 09, 2021) Dec 2019 to Jan 2021 15/47,910 Headache 44% (13% to 78%)
Misra (Dec 07, 2021) Dec 2019 to Dec 2020 350/145,721 Headache 13% (12% to 15%)Dizziness 7% (5% to 8%)Confusion 11% (7% to 16%)Impaired consciousness 7% (5% to 10%)
Rogers (Jun 3, 2021) Dec 2019 to Jul 2020 147/ 99,905 Headache 20.7% (16.1% to 26.1%)Altered mental status 8.2% (4.4% to 14.8%)
Wang (Jun 11,2020) Dec 2019 to May 2020 41/3,837 Headache 9.2% (7.2 to 11.2)Dizziness 10.0% (5.9% to 14.2%)Confusion 5.2% (1.7% to 12.2%)
Collantes (Jul 15,2020) Jan 2020 to Apr 2020 35/6,335 Headache 12% (10% to 14%)Dizziness 8% (5% to 12%)Confusion 5% (2% to 14%)
Abdullahi (Jun 26, 2020) Dec 2019 to Apr 2020 51/11,069 Headache 12% (9% to 15%)Dizziness 10% (3% to 19%)Impaired consciousness 2% (1% to 2%)
Pinzon (May 29, 2020) [23] Jan 2020 to Apr 2020 33/7,559 Headache 10.9% (8.62% to 13.51%)Dizziness 8.7% (5.02% to 13.43%)Impaired consciousness 3.8% (0.16% to 12.04%)
Rogers (May 18, 2020) Jan 2020 to Apr 2020 7/3,559 Altered consciousness: 21% of patients who subsequently died
CI, confidence interval; COVID-19, coronavirus disease 2019; IQR, Interquartile range.